Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Advancement in Treating Uncommon EGFR Mutations: Key Takeaways

January 3rd 2024

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

FDA Issues Complete Response Letter to Sotorasib for KRAS G12C–Mutated NSCLC

January 2nd 2024

The FDA has issued a complete response letter to the supplemental new drug application seeking the full approval of sotorasib for patients with KRAS G12C–mutated non–small cell lung cancer.

Lung Specialist Finds His “Sweet Spot” at the Intersection of Medicine and Technology

January 1st 2024

David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.

Advancements in Squamous NSCLC Treatment: Subgroup Analysis from EMPOWER-Lung Trials

December 29th 2023

Eduardo Santos, MD, FACP, FCCP, delves into advancements in the treatment of squamous NSCLC, emphasizing crucial insights from the EMPOWER-Lung01 and EMPOWER-Lung03 subgroup analysis.

EMPOWER-Lung3: Evaluating Cemiplimab Plus Chemotherapy in Advanced NSCLC

December 29th 2023

Eduardo Santos, MD, FACP, FCCP, highlights key takeaways from the latest EMPOWER-LUNG03 data and discusses the impact of these findings on the treatment setting.

Future Perspectives in KRAS G12C-Mutated NSCLC

December 28th 2023

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.

Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

December 28th 2023

Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.

Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight

December 27th 2023

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

Antibody-Drug Conjugates in EGFR-Mutant NSCLC

December 27th 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

December 27th 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations

December 27th 2023

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

State of the Science Summit - Lung Cancer: Chaired by Joshua K Sabari, MD

December 22nd 2023

State of the Science Summit - Lung Cancer: Chaired by Joshua K Sabari, MD

Patritumab Deruxtecan BLA Receives Priority Review in NSCLC

December 22nd 2023

The FDA has accepted and granted priority review to the biologics license application seeking the approval of the HER3-directed antibody-drug conjugate patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Immunotherapy-Based Treatment Strategies in Advanced NSCLC

December 22nd 2023

Eduardo Santos, MD, FACP, FCCP, provides an overview of immunotherapy-based treatment strategies for advanced NSCLC, outlining key factors influencing treatment selection.

Updates in Adjuvant Immunotherapy for NSCLC: Conference Highlights 2023

December 22nd 2023

Dr. Eduardo Santos, MD, FACP, FCCP, examines immunotherapy-based treatment approaches for NSCLC in the adjuvant setting, highlighting updates from KEYNOTE-091.

NCCN Adds 2 Category 1 Recommendations for Amivantamab in NSCLC Clinical Practice Guidelines

December 21st 2023

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines for Non–Small Cell Lung Cancer for 2024 to include 2 new category 1 recommendations for amivantamab alongside chemotherapy in patients with treatment-naive, EGFR-mutated advanced NSCLC.

sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC

December 21st 2023

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

December 21st 2023

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

December 21st 2023

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.